dusigitumab

Home
Ligands
dusigitumab

GtoPdb Ligand ID: 7749

Synonyms: MEDI-573

Comment: Dusigitumab is an investigational monoclonal antibody which neutralises circulating insulin-like growth factor (IGF)-I and IGF-2. These growth factors regulate cell growth, survival, differentiation, and transformation. Antibody-mediated ligand neutralisation prevents these growth hormones from activating signalling via both IGF1R and IR-A (insulin receptor isoform A, Uniprot identifier P06213-2, RefSeq protein NP_001073285).
Peptide sequence alignment suggests that dusigitumab is antibody 7-159-1 in patent US7939637 [2].

References
1. Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J et al.. (2014) Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clin Cancer Res, 20 (18): 4747-57. [PMID:25024259]
2. Raeber O, Gazit-Bornstein G, Yang X, Cartlidge SA, Tonge DW. Insulin-like growth factor antibodies and uses thereof. Patent number: US7939637. Assignee: Medimmune Limited. Priority date: 13/12/2005. Publication date: 10/05/2011.

References

1. Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J et al.. (2014)
Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors.
Clin Cancer Res, 20 (18): 4747-57. [PMID:25024259]

2. Raeber O, Gazit-Bornstein G, Yang X, Cartlidge SA, Tonge DW.
Insulin-like growth factor antibodies and uses thereof.
Patent number: US7939637. Assignee: Medimmune Limited. Priority date: 13/12/2005. Publication date: 10/05/2011.